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ABSTRACT Metagenomic shotgun sequencing (MSS) is a revolutionary approach to
viral diagnostic testing that allows simultaneous detection of a broad range of vi-
ruses, detailed taxonomic assignment, and detection of mutations associated with
antiviral drug resistance. To enhance sensitivity for virus detection, we previously de-
veloped ViroCap, a targeted sequence capture panel designed to enrich nucleic acid
from a comprehensive set of eukaryotic viruses prior to sequencing. To demonstrate
the utility of MSS with targeted sequence capture for detecting clinically important
viruses and characterizing clinically important viral features, we used ViroCap to ana-
lyze clinical samples from a diagnostic virology laboratory containing a broad range
of medically relevant viruses. From 26 samples, MSS with ViroCap detected all of the
expected viruses and 30 additional viruses. Comparing sequencing after capture en-
richment with standard MSS, we detected 13 viruses only with capture enrichment
and observed a consistent increase in the number and percentage of viral sequence
reads as well as the breadth and depth of coverage of the viral genomes. Compared
with clinical testing, MSS enhanced taxonomic assignment for 15 viruses, and
codons associated with antiviral drug resistance in inﬂuenza A virus, herpes simplex
virus (HSV), human immunodeﬁciency virus (HIV), and hepatitis C virus (HCV) could
be analyzed. Overall, in clinical samples, MSS with targeted sequence capture pro-
vides enhanced virus detection and information of clinical and epidemiologic rele-
vance compared with clinical testing and MSS without targeted sequence capture.
KEYWORDS diagnostic testing, sequencing, targeted sequence capture, virology
Metagenomic shotgun sequencing (MSS) has the power to transform diagnostictesting by creating a platform to simultaneously detect and characterize all
potential pathogens present in a sample. MSS is not constrained by a priori knowledge
of which pathogens might be present and is tolerant to sequence variation that could
cause targeted molecular tests to fail (1, 2). In addition to pathogen detection, MSS
provides information about clinically relevant genomic features, such as taxonomic
classiﬁcation, drug resistance, and virulence factors (1–6).
MSS has been used to characterize the “virome,” the viral component of the
microbiome, in a growing number of studies, demonstrating clinical applications in
which viral diagnostic testing is expanded or enhanced. In a previous study, we deﬁned
speciﬁc viruses associated with unexplained fever in young children (7, 8), and MSS
allowed us to detect viruses that were not included in the extensive PCR testing that
had been carried out on the samples (7–9). MSS has also been used to detect numerous
unsuspected viruses from individuals with a variety of clinical syndromes, including
encephalitis and fever of unknown origin (10–15). In addition, MSS has been used to
demonstrate that anellovirus blooms are associated with immunosuppression in trans-
plant patients and that lower levels of anelloviruses are associated with graft rejection
(6, 16, 17). These experiences suggest that expanding the repertoire of current clinical
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tests for viruses could be useful and that sequencing could be a powerful, compre-
hensive diagnostic tool. A limitation to using MSS for viral diagnostics, however, has
been the relatively low sensitivity of detection compared with standard PCR-based
molecular tests (5, 7, 18).
We previously reported our development of ViroCap (19), a panel of targeted
sequence capture probes that enriches viral nucleic acid from the complete genomes
of all vertebrate viruses prior to MSS and increases the sensitivity of virus detection (19,
20). Important advantages compared to PCR are that the viruses detected are not
limited by primer and probe sets, that sequence variation of primer and probe sites
does not affect detection, and that there is the potential to provide more highly
granular information about detected viruses (19). Our aim in this study was to show the
impact of using MSS with targeted sequence capture enrichment on viral detection and
characterization compared to previous clinical testing on samples submitted to a
diagnostic virology laboratory. The samples were selected to represent a broad range
of viruses detected in a diagnostic laboratory based in an academic referral hospital. All
samples were analyzed by MSS with and without ViroCap to allow us to evaluate the
additive value of MSS with targeted sequence capture enrichment for improving virus
detection and generating additional relevant clinical information.
MATERIALS AND METHODS
Samples were tested under a protocol approved by the Washington University School of Medicine
Human Research Protection Ofﬁce for testing of residual material from specimens that had been
submitted for routine testing in the Diagnostic Virology Laboratory at St. Louis Children’s Hospital. For
this study, we selected 26 samples submitted for testing in the Diagnostic Virology Laboratory at St. Louis
Children’s Hospital, including 24 positive samples that each had one virus detected by that laboratory
and 2 with no viruses detected (Table 1). Positive samples were selected to represent a broad range of
viruses detectable using routine tests, mostly PCR based, including herpesviruses, polyomaviruses, and
common respiratory and gastrointestinal viruses. DNA and RNA viruses were both represented. Sample
types included whole blood, plasma, cerebrospinal ﬂuid (CSF), nasopharyngeal (NP) swabs, tracheal
aspirates, skin swabs, and stool.
Swabs were collected in 3 ml of universal transport medium and were vortexed to free sample
material from the swab. One hundred microliters was removed and loaded on the NucliSENS easyMAG
instrument (bioMérieux, Inc., Marcy l’Etoile, France). Total nucleic acid was eluted with 100 l of elution
buffer. Stool (100 l of liquid stool or 100 g of formed stool) was added to 900 l of lysis buffer, and
the sample was vortexed on the high setting for 10 min at room temperature. Lysis was continued for
an additional 10 min at room temperature without vortexing. Samples were centrifuged for 2 min at
14,000 rpm, and 200 l of the lysate was loaded onto the easyMAG instrument. Total nucleic acid was
eluted in 70 l of elution buffer. For whole blood, 200 l of blood was combined with 2 ml of warm lysis
buffer and vortexed for 30 s to prevent clotting; 100 l of silica from the easyMAG instrument was then
added to the sample, followed by vortexing for 15 s. The sample and silica were then added to the
easyMAG instrument for extraction, and total nucleic acid was eluted in 100 l of elution buffer. CSF,
plasma, and urine samples were loaded directly onto the easyMAG instrument following an onboard lysis
protocol. For CSF, 1 ml was extracted and total nucleic acid was eluted in 50 l elution buffer; for plasma
and urine, 100 l was extracted and eluted in 100 l elution buffer.
Samples were prepared so that both DNA and RNA viruses could be detected in the same sample,
as previously described (19). In brief, 9 l of total nucleic acid from each sample was used as input
material. RNA was reverse transcribed with Superscript IV (Thermo Fisher Scientiﬁc, Waltham, MA) using
random nonamers tagged with a conserved sequence (5=-GTTTCCCAGTCACGATA-3=) followed by
second-strand synthesis with Sequenase (Thermo Fisher Scientiﬁc, Waltham, MA). DNA and cDNA were
subsequently ampliﬁed using primers targeting the conserved sequence using AccuPrime Taq DNA
polymerase (Thermo Fisher Scientiﬁc, Waltham, MA) with the following cycling conditions: 94°C for 2 min;
15 cycles of 94°C for 30 s, 40°C for 30 s, 50°C for 30 s, and 72°C for 1 min; and hold at 4°C. The DNA-cDNA
mixture was sheared to an average length of 500 bp using the Qsonica Q800R instrument (Qsonica,
Newtown, CT). Dual-indexed sequencing libraries were constructed with the Swift Biosciences Accel
NGS-2S library kit (Swift Biosciences, Ann Arbor, MI). Sequencing libraries were pooled in two groups
consisting of 13 or 14 samples each, and then each pool was divided into two portions. The ﬁrst portion
was sequenced directly on one lane on the Illumina HiSeq 2500 instrument (Illumina, San Diego, CA),
generating 125-base paired-end sequences. The second portion was subjected to targeted sequence
capture with ViroCap (19) prior to sequencing on a second lane on the Illumina instrument. ViroCap
probes were synthesized by Roche NimbleGen (Madison, WI), and capture was carried out according to
the manufacturer’s instructions. Viral sequences were identiﬁed in the sequence data based on nucle-
otide and translated sequence alignments against all viral reference sequences in the NCBI nucleotide
and nonredundant-protein databases, followed by conﬁrmation alignments against the complete NCBI
nucleotide and nonredundant-protein databases, as previously described (19, 21). Sequence coverage
metrics were determined using RefCov as described previously (19). Due to the clinical focus of this study,
we are reporting only vertebrate viruses. To avoid false positives resulting from index swapping during
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capture (22–24), we established a threshold for each virus, consisting of 0.1% of the total reads for that
virus in the appropriate pool. This was based on published studies and is consistent with our experiences
dealing with dual-indexed sequencing libraries and the HiSeq 2500 platform (22–24). The threshold
number of reads for the virus was subtracted from the raw observed number of reads to establish the
reported number of sequence reads. Subsequently, samples were considered positive for a virus if the
reported number of sequence reads was 1 after subtraction of the threshold.
Single-nucleotide variants in the HIV-1, inﬂuenza A virus, and herpesvirus genomes were identiﬁed
using VarScan2 (25, 26). HIV-1 resistance mutations were evaluated using the HIV Drug Resistance
Database (27). Inﬂuenza virus variants were evaluated using the Inﬂuenza Database Project (28) through the
website at https://www.ﬂudb.org/. Speciﬁcally, we used the “Identify Sequence Features in Segments” tool
(https://www.ﬂudb.org/brc/inﬂuenza_batch_submission.spg?methodNewSFVTAnnotation&decorator
inﬂuenza). Herpesvirus variants were evaluated using the NIAID Virus Pathogen Database and Analysis
Resource (ViPR) (29) through the website at http://www.viprbrc.org using the Antiviral Resistance Risk
Assessment tool for the Herpesviridae (https://www.viprbrc.org/brc/antiviralResistanceRisk.spg?method
ShowCleanInputPage&decoratorherpes). The hepatitis C virus (HCV) genome was assembled with
IDBA-UD (30). Variants and assemblies were manually reviewed with Tablet (31). The inﬂuenza B virus
lineage was determined based on the sequence as described previously (32). Polyomavirus BK (BKPyV)
subtypes were determined using the algorithm of genomic variants described by Morel et al. (33). The
metapneumovirus lineage was determined based on the genomic determinants described by van den
Hoogen et al. (34). The varicella-zoster virus (VZV) vaccine strain was distinguished based on genomic
features described by Loparev et al. (35).
Sequencing results were conﬁrmed using virus-speciﬁc PCR assays (8, 35). Epstein-Barr virus (EBV)
DNA was measured using the PCR assay described by Wandinger et al. (36). This assay ampliﬁes a
segment of the BamHI W segment of the EBV genome. The presence of human herpesvirus 6 (HHV-6) was
conﬁrmed using the PCR assay described by Cone et al. (37). This assay ampliﬁes a segment of the large
tegument protein gene. The presence of HHV-7 DNA was conﬁrmed using the PCR assay described by
Kidd et al. (38). This assay ampliﬁes a segment of the homolog of the HHV-6 U42 gene. The presence of






threshold Other test(s) performedc
Additional virus(es)
detected by MSSd
1 Dermal swab HSV-2 LDT 24.5 VZV HPV 122
2 CSF HSV-1 Eragen ASR 30.8 Enterovirus, Toxoplasma gondii, EBV
3 NP Inﬂuenza B virus RVP NA None
4 Urine BKPyV LDT 16.9 None
5 Plasma HHV-6 LDT NA Adenovirus, CMV, HSV, EBV HPV 128
6 CSF JCPyV LDT NA VZV, HSV, CMV, EBV, Toxoplasma gondii HIV-1
7 NP Rhinovirus/enterovirus RVP None HHV-7
8 NP None NA NA None TTMV, HMPV, HRV-C
9 Plasma Parvovirus B19 Focus ASR 33.1 None TTMDV 1
10 NP RSV RVP NA None HHV-7, HPV 107
11 CSF Parechovirus LDT 36 Enterovirus, HSV
12 CSF Enterovirus GeneXpert 32.7 None
13 Stool Norovirus G2 Focus ASR 18.3 Rotavirus antigen HPV 45
14 Whole blood None NA NA Ehrlichia/Anaplasma EBV
15 Whole blood CMV Qiagen ASR 27.3 None HCV 4g, TTV 10
16 NP Parainﬂuenza virus 3 RVP NA None
17 NP Coronavirus NL63 RVP NA None
18 NP Human
metapneumovirus
RVP NA None HHV-6, HHV-7
19 TA Inﬂuenza A virus H3 RVP NA None HPV 23, HPV 48,
EBV, TTV
20 Skin scraping VZV, wild type LDT 17.9 Unknown HPV 100
21 Whole blood CMV Qiagen ASR 25.2 None TTV
22 Whole blood EBV LDT 34.1 None HHV-7, TTV 7
23 Whole blood EBV LDT 30.7 None TTMDV
24 NP Adenovirus RVP NA None HPV 13, HHV 6,
TTMV ALH8
25 Stool Rotavirus Antigen assay NA Unknown TTV 13
26 Skin scraping VZV vaccine strain LDT 30.2 Unknown TTMV
aAbbreviations: NP, nasopharyngeal; CSF, cerebrospinal ﬂuid; TA, tracheal aspirate; LDT, laboratory-developed test; ASR, analyte-speciﬁc reagent; RVP, respiratory virus
panel; HSV, herpes simplex virus; VZV, varicella-zoster virus; EBV, Epstein-Barr virus; CMV cytomegalovirus; BKPyV, BK polyomavirus; JCPyV, JC polyomavirus; TTV,
torque teno virus; TTMV, torque teno minivirus; TTMDV, torque teno midivirus; NA, not applicable.
bPCR unless otherwise indicated.
cThese tests were ordered by physicians caring for the patients. Results of indicated assays were negative.
dViruses in bold were detected by MSS with enrichment but not without enrichment. All viruses detected in the clinical lab were also detected by MSS without and
with enrichment, except for the adenovirus detected by the clinical laboratory in sample 24 (in bold), which was detected by MSS with enrichment but not without
enrichment.
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VZV DNA and the distinction between the wild-type and OKA vaccine viruses were conﬁrmed or
determined using the PCR assay described by Loparev et al. (35). This assay is a LightCycler assay that
ampliﬁes a 301-bp segment of VZV open reading frame (ORF) 62, which includes a polymorphic site at
position 106262. The distinction between wild-type and vaccine viruses is made on the basis of melt
curves. The human rhinovirus (HRV) and human metapneumovirus (HMPV) were conﬁrmed using the
GenMark Dx respiratory virus panel (GenMark, Carlsbad, CA).
The percentage of viral reads was calculated for each virus in each sample. This represents the
number of viral sequences aligned to the reference genome divided by the total number of sequences
generated for that sample. The breadth of coverage represents the percentage of the genome length
represented by the sequence data. The depth of coverage is the per-position redundancy in sequence
reads that align to the genome, and the mean is the average depth calculated across each base of the
reference genome. Statistical analysis of the difference in percentage of viral reads, breadth of coverage
(percent), and mean depth of coverage between MSS without and with targeted sequence capture was
analyzed using the Wilcoxon signed-rank test. Analyses were limited to the viruses detected in the clinical
laboratory.
Accession number(s). Sequence data for the 26 samples were submitted to the Sequence Read
Archive under accession numbers SAMN05713695 to SAMN05713718 and SAMN05713721 to
SAMN05713722.
RESULTS
All samples were tested by standard MSS and MSS enriched using ViroCap targeted
sequence capture. Both sequencing approaches detected every virus that had been
detected in the clinical laboratory, with the exception of a single NP swab sample in
which adenovirus was detected only using targeted sequence capture. In addition, the
sequencing methods detected 30 additional viruses (Table 1), most of which were
viruses that are not tested for in the clinical laboratories or were from viral tests that
were not requested for these samples. Comparing standard sequencing with sequenc-
ing after capture enrichment, we observed consistent and substantial increases in the
percentage of viral sequence reads obtained and depth and breadth of sequence
coverage for each genome (see Table S1 in the supplemental material). These differ-
ences were all highly statistically signiﬁcant (Wilcoxon test, P  0.001). Data for
individual segments of viruses with segmented genomes are shown in Table S2 in the
supplemental material.
Of the 30 viruses detected by sequencing that had not been detected in the clinical
laboratory, 18 (60%) were detected both by MSS alone and by MSS with ViroCap
targeted sequence capture, and 12 (40%) were detected only using capture enrichment
(Table 1). The most common virus group detected only by sequencing was anellovi-
ruses (n  10), which are not tested for in clinical laboratories, followed by human
papillomavirus (HPV) (n  8). The anelloviruses included 5 alphatorqueviruses (torque
teno virus [TTV]), 3 betatorqueviruses (torque teno minivirus [TTMV]), and 2 gamma-
torqueviruses (torque teno midivirus [TTMDV]). The HPVs included multiple types and
were detected in diverse samples. Only one was a high-risk type. Notably, HIV was
detected in a single CSF sample and HCV was detected in a single whole-blood sample,
in each case from patients previously known to be infected with these viruses. Other
viruses detected by sequencing but not initial clinical testing included Epstein-Barr
virus (EBV) (n  2), HHV-6 (n  2), HHV-7 (n  4), human metapneumovirus (HMPV)
(n  1), and human rhinovirus (HRV) (n  1). Testing for these herpesviruses had not
been requested in the clinical laboratory for the samples in which these viruses were
detected; however, we subsequently conﬁrmed the presence of these viruses by PCR.
HMPV and HRV-C were detected in a single NP sample (sample 8) that was included in
the set as a sample that was negative after clinical testing, which was done using the
BioFire respiratory multiplex panel that includes assays for these viruses. The signal in
the sequence data was strong for the HRV (40,000 sequence reads, with 80% of the
genome covered after enrichment) and weaker for the HMPV (100 sequence reads,
with 8% of the genome covered after enrichment), which was detected only using
capture enrichment (Tables 1 and S1). These viruses were subsequently conﬁrmed
using a different multiplex respiratory panel (GenMark). The other negative sample
from the diagnostic virology laboratory (sample 14) had been submitted for molecular
testing for Ehrlichia and Anaplasma and had been negative for those agents but had
not been tested for viruses. Sequencing results for this sample revealed no viral
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sequences with standard MSS and 9 sequence reads corresponding to EBV with ViroCap
enrichment (Table S1). EBV was subsequently conﬁrmed with a targeted PCR assay.
Sequence analysis allowed us to characterize the viruses detected in greater detail
than was possible in the clinical laboratory (Table 2). We were able to determine the
subtype of inﬂuenza A virus in sample 19 and the lineage of inﬂuenza B virus in sample
3. Other viruses identiﬁed to a higher taxonomic level than was done by the clinical
virology laboratory were RSV-A, HRV-C11, human parechovirus type 3, enterovirus B,
norovirus GII.4, human mastadenovirus C, BKPyV type 1, and rotavirus G12P[8]. For
most of these, the increased detail was achieved with or without capture, although the
two EBVs were identiﬁed as EBV-1 only with capture, and the human mastadenovirus
C and HHV-6, both in sample 24, were not detected at all by MSS without capture.
We also examined detection of drug resistance by MSS (Table 3). The sequence of
the inﬂuenza A virus neuraminidase gene indicated that the virus was susceptible to
the neuraminidase inhibitors oseltamivir and zanamivir, and the sequence of the gene
encoding the matrix 2 protein indicated that the virus was susceptible to adamantanes.
The herpes simplex virus 2 (HSV-2) detected in sample 1 had sequences covering the





MSS without capture MSS with capture
3 Inﬂuenza B virus Inﬂuenza B virus, Yamagata lineage Inﬂuenza B virus, Yamagata lineage
4 BKPyV BKPyV subtype 1a BKPyV subtype 1a
5 HHV-6 HHV-6B HHV-6B
7 Rhinovirus/enterovirus Rhinovirus C11 Rhinovirus C11
10 RSV RSV-A RSV-A
11 Parechovirus HPeV-3 HPeV-3
12 Enterovirus Enterovirus B Enterovirus B
13 Norovirus GII Norovirus GII.4 Norovirus GII.4
18 HMPV HMPV lineage A HMPV lineage A
19 Inﬂuenza A virus H3 Inﬂuenza A virus H3N2 Inﬂuenza A virus H3N2
22 EBV EBV EBV-1
23 EBV EBV EBV-1
24 Adenovirus Not detected Human mastadenovirus C
24 HHV-6 Not detected HHV-6B
25 Rotavirus Human rotavirus A, G12P[8] Human rotavirus A, G12P[8]
aIncludes viruses for which MSS provided enhanced taxonomic identiﬁcation. Abbreviations: HSV, herpes simplex virus; BKPyV, BK polyomavirus; HHV-6, human
herpesvirus 6; RSV, respiratory syncytial virus; HPeV, human parechovirus; HMPV, human metapneumovirus; EBV, Epstein-Barr virus.
TABLE 3 Detection of antiviral resistance genotypes by MSS without and with capture
Sample no. Virus Gene
Relevant drug or
drug class
No. of codons queried (codon
identiﬁcation)
No. of codons with sequence
available from MSS:





6 (V116, E119, I222, Q136, D198,
H274)
6 6





Acyclovir 19 (R34, R51, G59, S66, A72, P85,
N100, I101, T131, L158, R177,














39 (HIV Drug Resistance
Database [27])
10 22
Protease Protease inhibitors 33 (HIV Drug Resistance
Database [27])
0 33
Integrase Integrase inhibitors 23 (HIV Drug Resistance
Database [27])
22 22
15 Hepatitis C virus
genotype 4
NS5A NS5A inhibitors 3 (L28, M31, T58) 0 2
Protease (NS3) Protease inhibitors 2 (Y56, D168) 0 0
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thymidine kinase and polymerase genes, and analysis did not reveal any mutations or
polymorphisms known to be associated with resistance to acyclovir, foscarnet, or
cidofovir (29). Relevant genome coverage for determining antiviral susceptibility/resis-
tance genotypes was not rendered for the HSV-1 detected in sample 2. The HCV
genome detected in sample 15 was typed as subtype 4g but was divergent from the
HCV references in the NCBI nucleotide database, with the two largest assembled
contigs (1.8 kb and 900 bp) matching at 85 to 87% nucleotide identity over their
lengths compared with the most similar virus. After assembly, we had contigs that
covered NS5A at positions L28 and M31, allowing us to conﬁrm that this virus did not
contain the characterized resistance mutations at those positions (39). We did not have
coverage of NS5A position T58 or NS3 positions Y56 and D168, so we were unable to
determine whether the virus carried mutations for resistance at those sites. The HIV-1
genome had sufﬁcient sequence coverage of the reverse transcriptase (RT)-, integrase-,
and protease-coding sequences to assess resistance to each of these classes (27).
Speciﬁcally, the virus had sequence variants that were associated with potential
low-level resistance to the RT inhibitors abacavir and tenofovir, intermediate resistance
to zidovudine, and high-level resistance to the nonnucleoside RT inhibitors efavirenz
and nevirapine. The sequence also indicated susceptibility to the nucleoside RT inhib-
itor lamivudine and the nonnucleoside RT inhibitors emtricitabine, etravirine, and
rilpivirine. The sequence of the protease gene showed high-level resistance to the
protease inhibitors atazanavir and lopinavir and intermediate resistance to darunavir.
Finally, the sequence of the polymerase gene also indicated high-level resistance to the
integrase strand transfer inhibitors dolutegravir, elvitegravir, and raltegravir. We did not
have sequence coverage of the cytomegalovirus (CMV) UL54 or UL97 genes, so we
could not assess drug resistance in those genomes. Determination of the resistance
genotype was substantially facilitated using capture for the HSV genes and the HIV
polymerase and reverse transcriptase genes.
We also detected some viruses by sequencing that were not conﬁrmed by virus-
speciﬁc PCR and probably represented laboratory contamination. We did not include
these in our results in Table 1 or in the total numbers of viruses detected. We detected
10 enterovirus D68 sequence reads without capture and approximately 2,000 reads
with capture in 4 samples (5, 6, 9, and 10 sequences) and a single rotavirus read in 1
sample with capture (11 sequences). We had recently been studying both enterovirus
D68 and rotavirus in our laboratory, and the sequences were from the same types that
we had been examining. To test the possibility that these were laboratory contami-
nants, we reextracted nucleic acid from the original samples and tested the new
extracts by PCR. The presence of the viruses was not conﬁrmed on the newly extracted
nucleic acid. We also detected 4 EBV reads in sample 7 with capture, which were not
conﬁrmed by virus-speciﬁc PCR. Lastly, we detected VZV in 3 samples, 2 with and
without capture and 1 only with capture. In those that were detected with and without
capture, read numbers were higher with capture. Although the numbers of sequence
reads were substantial with capture, the presence of VZV in these samples was not
conﬁrmed by virus-speciﬁc PCR.
DISCUSSION
Application of MSS to diagnostic virology has great appeal based on the capability
for (i) broad-range detection and (ii) detailed taxonomic characterization (40–47) and
for characterization of antiviral resistance genotypes (48). Our ﬁndings in this study
illustrate and quantitate these advantages using actual clinical samples and measure
the further enhancement achieved by the use of targeted sequence capture to improve
the sensitivity of standard metagenomic shotgun sequencing.
To assess the gain of yield resulting from adding targeted sequence capture to MSS,
we applied these methods to a group of samples known to contain a broad range of
viruses detected in diagnostic virology laboratories. Using paired aliquots from the
same sequencing libraries, we directly compared the impact of MSS using our standard
viral metagenomic sequencing procedure in parallel with the same procedure with the
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addition of enrichment with targeted sequence capture using the ViroCap reagent that
we have previously described (19). ViroCap contains approximately 2 million capture
probes that span the genomes of all vertebrate viruses known at the time the reagent
was synthesized in 2014. In the present study, standard MSS increased the yield of viruses
detected by 75% over that obtained by standard clinical testing due to the ability of
sequencing to broadly detect viruses not speciﬁcally included in requested clinical tests,
and the addition of ViroCap increased the yield by an additional 50% over standard clinical
testing, more than doubling the yield of viruses that were detected in the diagnostic
laboratory. While we chose samples containing common clinical viruses for this study,
ViroCap has the capability to enrich genomes from uncommon viruses and those with
divergent genome sequences (19). The increased yield of viruses included some with
obvious clinical signiﬁcance, most importantly, HIV, which was detected without and
with capture in 1 sample, and HCV, which was detected only with capture in 1 sample.
While in these cases the viral infections had been previously diagnosed, sequencing has
the capability of detecting unsuspected chronic viral infection, such as infection with
HIV, HCV, or HBV, when evaluating samples for acute viral infections, which can have
important beneﬁts for the patient. As metagenomic sequencing is increasingly applied
as a diagnostic tool, it will be important for providers and patients to understand this
capability.
Other viruses detected by sequencing but not in the initial clinical tests were HMPV,
HRV-C, HHV-6 and -7, EBV, and HPV. Each of these viruses can be pathogenic for
humans but also can be found in the absence of symptoms. HMPV and HRV-C were
found in an NP sample that was negative when tested by a multiplex molecular panel
in the diagnostic laboratory. The HMPV was detected only using targeted capture
enrichment and may have been present at a low level that escaped detection by the
multiplex assay and MSS without enrichment. The HRV-C was detected both without
and with ViroCap, with more than 40,000 reads detected with capture enrichment. It is
possible that HRV-C was not detected by the multiplex panel because of sequence
differences in the primer binding sites, as has been reported previously for RT-PCR
assays directed at human rhinoviruses, which are very diverse (1), and for human
parainﬂuenza virus (43). Because the primer sequences used in the multiplex assay are
not available, we cannot directly test this hypothesis. HHV-7 is commonly detected in
human samples, usually in the absence of disease manifestations (49). Of the 4 samples
with HHV-7 detected by sequencing, 3 were from the respiratory tract and 1 was whole
blood. Three were detected without and with targeted sequence capture enrichment,
and 1 was detected only with capture enrichment. HHV-6 was detected in two NP
samples. In one, viral sequences were detected only with targeted sequence capture
enrichment, and in the other, viral sequences were detected both without and with
capture enrichment. The pathogenicity of HHV-6 in these two cases cannot be deter-
mined by use of available clinical data from these patients. Finally, EBV was detected in
one whole-blood sample only with targeted sequence capture and in 1 tracheal
aspirate sample without and with capture enrichment.
The most frequently detected virus group in the MSS data that was not detected in
the diagnostic laboratory was anelloviruses, which are not tested for in the clinical
laboratory. They were detected in 38% of all samples, including diverse sample types
such as whole blood, plasma, nasopharyngeal secretions, and stool. This group of
viruses is not currently associated with any disease, but their quantitative level in
plasma has been identiﬁed as being informative regarding the state of the host
immune system (17, 50, 51). The family Anelloviridae includes 3 genera that are
considered human viruses: Alphatorquevirus (e.g., TTV), Betatorquevirus (e.g., TTMV), and
Gammatorquevirus (e.g., TTMDV). We detected members of each of these genera. The
use of ViroCap did not increase the number of samples positive for anelloviruses but
was uniformly associated with substantial increases in the breadth and depth of
genome coverage. The anelloviruses have extensive genome heterogeneity (52) We
showed previously that ViroCap can enrich anelloviruses with as little as 58% nucleotide
sequence identity to the included capture probes (19), so while ViroCap can enrich
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anelloviruses with that level of genetic diversity, it is possible that some more-divergent
anelloviruses were not enriched.
The second most common family of viruses detected by MSS was papillomaviruses.
These viruses were detected in only one sample by standard MSS and in 8 samples with
targeted sequence capture enrichment, including diverse sample types such as whole
blood, plasma, NP swab, tracheal aspirate, skin, and stool. Each sample contained a
different type of papillomavirus, reﬂecting the known diversity of human papillomavi-
ruses. Even with use of capture enrichment, the number of sequence reads was
typically low (see Table S1 in the supplemental material). In blood or plasma samples,
it is likely that these viruses represent contamination of samples from the skin, the most
common site where papillomaviruses are present, during sample acquisition. While in
these cases papillomaviruses were not associated with a clinical presentation, this work
demonstrates the utility of using MSS with ViroCap to enhance detection of papillo-
maviruses. This could have clinical application for detecting high-risk papillomaviruses
associated with developing cancers, including head-and-neck and cervical cancers,
possibly even when the viruses are present at very low levels and before dysplasia or
other clinical phenotypes emerge.
In addition to detecting viruses present in the sample, MSS also produced some
sequence reads that were probably the result of laboratory contamination. We sus-
pected that sequence reads represented contamination when the presence of the viral
nucleic acid in the original sample was not conﬁrmed by virus-speciﬁc PCR. In the cases
of enterovirus D68 and rotavirus, the suspicion of contamination was heightened
because work with these viruses had been done previously in our laboratory. In the
case of VZV, we suspect contamination because VZV was found in 3 different samples
and not conﬁrmed by virus-speciﬁc PCR. In contrast, in the 2 samples in which VZV was
detected in the diagnostic lab and by MSS, the conﬁrmatory virus-speciﬁc PCR assay
was positive. Finally, the one case of EBV that was not conﬁrmed by virus-speciﬁc PCR
had a very low number of sequence reads. This discrepancy could reﬂect contamination
but might also result from failure of the virus-speciﬁc PCR to detect a very low level of
viral nucleic acid or from the presence of a mutation in the region of the genome
targeted by the primers. It is also possible that the VZV- and EBV-positive samples that
were not conﬁrmed by PCR represent situations in which we detected RNA transcripts
from the viruses during sequencing that were not detected with the PCR assays, as they
are directed at DNA genomes. Importantly, these ﬁndings highlight a current limitation
in application of MSS to clinical diagnosis. Deﬁning appropriate procedures and work
process controls to control and identify contamination must be a high priority as this
technology moves forward toward implementation in clinical medicine.
While targeted capture improves virus detection, there are several limitations to the
approach. The ﬁrst is the time required for the assay. In our experiments, we hybridized
the capture probes to the libraries for 72 h and then performed several additional hours
of sample handling prior to sequencing and analysis, adding days to the assay. Second,
viral genomes that are novel or highly divergent from the capture probe sequences will
not be enriched. This does not mean that the viruses could not still be detected in the
sequence data, but the signal would not be improved with capture. Finally, the cost of
capture probes could be prohibitive if only a few samples were assayed. However, if
samples are multiplexed, this cost can be offset.
In summary, this study further demonstrates the potential power of metagenomic
sequencing as a viral diagnostic method, conﬁrming its high sensitivity, ability to detect
a broad range of viruses, capacity to provide detailed taxonomic identiﬁcation, and
capacity to characterize antiviral resistance genotypes. All of these capabilities were
enhanced by including a sequence capture step targeting viruses. Metagenomic se-
quencing has the capability to bring about a paradigm shift in diagnostic virology.
Challenges going forward are to simplify and standardize processes at each step from
sample collection to bioinformatics analysis, to control sample cross-contamination,
and to lessen cost. A number of challenges related to clinical interpretation of the
extensive data provided by MSS also remain, including the signiﬁcance of viruses that
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are not known to be pathogenic or that are detected in unusual body sites and the
dilemma raised by detecting unsuspected viruses that may have major clinical impli-
cations, such as HIV and HCV. Ideally, future studies should involve the use of sequenc-
ing approaches to explore samples in which no pathogen was previously detected and
to focus on speciﬁc, larger cohorts of patients with similar symptoms or types of
infections (e.g., central nervous system infections, gastroenteritis, etc.) who do not have
a speciﬁc infection diagnosed.
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